HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Saturday.

HTGM has been the subject of a number of other reports. Zacks Investment Research raised HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Thursday, May 11th. Canaccord Genuity upped their price target on HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a “hold” rating in a research note on Wednesday, April 19th. Rodman & Renshaw upped their price target on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, May 16th. Finally, HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $5.75.

Shares of HTG Molecular Diagnostics (NASDAQ HTGM) traded up 5.71% on Friday, reaching $2.22. 112,780 shares of the company were exchanged. HTG Molecular Diagnostics has a 52 week low of $1.20 and a 52 week high of $13.25. The company’s market capitalization is $21.69 million. The company’s 50-day moving average is $2.43 and its 200-day moving average is $3.36.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.60). HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.80 million. On average, equities analysts expect that HTG Molecular Diagnostics will post ($2.25) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/12/htg-molecular-diagnostics-inc-htgm-lifted-to-sell-at-valuengine.html.

A number of institutional investors have recently added to or reduced their stakes in the company. UBS Group AG purchased a new position in HTG Molecular Diagnostics during the first quarter worth approximately $137,000. Two Sigma Securities LLC purchased a new position in HTG Molecular Diagnostics during the first quarter worth approximately $150,000. Granahan Investment Management Inc. MA purchased a new position in HTG Molecular Diagnostics during the first quarter worth approximately $228,000. Renaissance Technologies LLC increased its position in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock worth $130,000 after buying an additional 14,206 shares during the period. Finally, Vanguard Group Inc. increased its position in HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after buying an additional 37,841 shares during the period. Hedge funds and other institutional investors own 28.05% of the company’s stock.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.